The short version
- Why people research itAppetite and satiety support (amylin analog), often stacked with GLP-1s.
- What the evidence isHuman phase 2 data as a standalone and, more importantly, as CagriSema — the cagrilintide/semaglutide combination — where REDEFINE-1 reported ~22.7% weight loss at 68 weeks.
- What to watchVomiting that will not stop, risking dehydration and kidney strain.
How Cagrilintide works
Lipidated amylin-receptor agonist — suppresses appetite and glucagon and slows gastric emptying (no insulin stimulation); pairs with semaglutide as CagriSema.
Cagrilintide is a long-acting analog of amylin, and the problem it was built to solve is that amylin is an amyloid. The hallmark of the native pancreatic hormone is its high propensity to form amyloid fibrils, which is what made it a hard drug design problem in the first place; the earlier analog in this class needed three injections a day because of its short half-life Kruse 2021.
The receptor question here is not GLP-1 versus amylin. It is amylin versus calcitonin, and the structures say cagrilintide barely distinguishes them. An amylin receptor is the calcitonin receptor (CTR) in complex with a receptor-activity-modifying protein: CTR+RAMP1 is AMY1, CTR+RAMP2 is AMY2, CTR+RAMP3 is AMY3.
- Injectable
Research on Cagrilintide4 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human trials (CagriSema).
Human clinical evidence
Human phase 2 data as a standalone and, more importantly, as CagriSema — the cagrilintide/semaglutide combination — where REDEFINE-1 reported ~22.7% weight loss at 68 weeks. Phase 3 is complete for the combination; cagrilintide alone is not approved.
Correlative data
Little standalone real-world use; almost everyone running it is pairing it with a GLP-1, which is how it was developed and studied. Reported experience is of a smoother, less nauseating satiety than a GLP-1 alone.
How the mechanism reads
A long-acting amylin analog. Amylin is co-secreted with insulin and signals satiety through a different receptor system from GLP-1.
MechanisticAmylin agonism also slows gastric emptying, so the predicted interaction with a GLP-1 is additive on the GI side.
Mechanistic
Sources
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry 2021 · PMID 34288673
- Cao J, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications 2025 · PMID 40204768
- Gu YM, et al. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica 2025 · PMID 40847076
- Carvas AO, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine 2025 · PMID 40609154
- Nielsen MJF, et al. Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Clinical Pharmacokinetics 2026 · PMID 42228334
- Gabe MBN, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes, Obesity and Metabolism 2024 · PMID 39279639
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2025 · PMID 40544433
- Buse JB, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. The Lancet Diabetes & Endocrinology 2026 · PMID 42251859
- Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International Journal of Molecular Sciences 2021 · PMID 35008482
Cagrilintide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Insulin use or type 1 diabetes, since amylin analogs carry a severe hypoglycemia warning with insulin.
- Gastroparesis, because it slows gastric emptying further.
- Eating disorder history, as it strongly suppresses appetite.
- Pregnancy or planning one.
What’s expected
- Appetite falls through amylin receptor action in the brainstem and hypothalamus.
- Nausea and slower gastric emptying.
- Lower glucagon after meals with no direct insulin stimulation.
Watch for
- Vomiting that will not stop, risking dehydration and kidney strain.
- Severe upper abdominal pain.
- Shakiness and sweating if used alongside glucose-lowering drugs.
Labs that tell you it’s working
- HbA1c: the glucose effect works through slowed emptying and lower glucagon.
- Insulin (Fasting): amylin agonism does not stimulate insulin, so it should not climb.
- Comprehensive Metabolic Panel: kidney function and electrolytes during poor intake.
- Lipase: checked if abdominal pain appears.
Lipidated long-acting amylin receptor agonist: satiety, slowed gastric emptying and glucagon suppression; not a GLP-1 agonist. PMID 34288673 PMID 40609154
Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained
Cagrilintide FAQ4 common questions
- Is Cagrilintide approved for human use?
- No. Cagrilintide is a research compound.
- What is Cagrilintide researched for?
- Appetite and satiety support (amylin analog), often stacked with GLP-1s.
- Which labs show whether it's doing anything?
- HbA1c; Insulin; Comprehensive Metabolic Panel; Lipase: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Cagrilintide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





